James E Flynn Insider Trading Transactions
Get free email notifications about insider trading for James E Flynn.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of James E Flynn. James E Flynn is 10% Owner in CAS MEDICAL SYSTEMS INC ($CAMY.OB) and 10% Owner in AxoGen, Inc. ($LECT) and 10% Owner in PAR PHARMACEUTICAL COMPANIES, INC. ($PRX) and 10% Owner in Fibrocell Science, Inc. ($FCSC) and 10% Owner in STREAMLINE HEALTH SOLUTIONS INC. ($LANV) and 10% Owner in ANTARES PHARMA, INC. ($ATRS) and 10% Owner in VIA Pharmaceuticals, Inc. ($CAQ) and 10% Owner in DUSA PHARMACEUTICALS INC ($DUSA) and 10% Owner in HI TECH PHARMACAL CO INC ($HITK) and 10% Owner in AVADEL PHARMACEUTICALS PLC ($AVDL) and 10% Owner in INSPIRE PHARMACEUTICALS INC ($ISPH) and 10% Owner in RIGEL PHARMACEUTICALS INC ($RIGL) and 10% Owner in ARENA PHARMACEUTICALS INC ($ARNA) and 10% Owner in ISTA PHARMACEUTICALS INC ($ISTA) and 10% Owner in MEDICINES CO /DE ($MDCO) and 10% Owner in THIRD WAVE TECHNOLOGIES INC /WI ($TWTI) and 10% Owner in DYNAVAX TECHNOLOGIES CORP ($DVAX) and 10% Owner in Cyclacel Pharmaceuticals, Inc. ($CYCC) and Director in Talon Therapeutics, Inc. ($EMLR) and 10% Owner in LUMOS PHARMA, INC. ($NLNK) and 10% Owner in NITROMED INC ($NTMD) and 10% Owner in XENOPORT INC ($XNPT) and 10% Owner in EMAGEON INC ($EMAG) and 10% Owner in CATALYST BIOSCIENCES, INC. ($CBIO) and 10% Owner in ALIMERA SCIENCES INC ($ALIM) and 10% Owner in NeuroMetrix, Inc. ($NURO) and 10% Owner in NxStage Medical, Inc. ($NXTM) and 10% Owner in aTYR PHARMA INC ($LIFE) and 10% Owner in Vanda Pharmaceuticals Inc. ($VNDA) and 10% Owner in XERIS PHARMACEUTICALS INC ($XERS) and Director in PROTEON THERAPEUTICS INC ($PRTO) and 10% Owner in eHealth, Inc. ($EHTH) and 10% Owner in ZAFGEN, INC. ($ZFGN) and 10% Owner in NeurogesX Inc ($NGSX) and 10% Owner in Invuity, Inc. ($IVTY) and 10% Owner in Dicerna Pharmaceuticals Inc ($DRNA) and 10% Owner in CONSTELLATION PHARMACEUTICALS INC ($CNST) and 10% Owner in TriVascular Technologies, Inc. ($TRIV) and 10% Owner in Auspex Pharmaceuticals, Inc. ($ASPX) and 10% Owner in Neos Therapeutics, Inc. ($NEOS) and 10% Owner in Schrodinger, Inc. ($SDGR) and 10% Owner in CytomX Therapeutics, Inc. ($CTMX) and Director in Acutus Medical, Inc. ($AFIB) and 10% Owner in Annexon, Inc. ($ANNX) and 10% Owner in Aclaris Therapeutics, Inc. ($ACRS) and 10% Owner in Syros Pharmaceuticals, Inc. ($SYRS) and 10% Owner in Mallinckrodt plc ($MNK) and 10% Owner in Loxo Oncology, Inc. ($LOXO) and 10% Owner in Adverum Biotechnologies, Inc. ($AAVL) and 10% Owner in REGENXBIO Inc. ($RGNX) and 10% Owner in Recro Pharma, Inc. ($REPH) and 10% Owner in Nivalis Therapeutics, Inc. ($NVLS) and Director in Nivalis Therapeutics, Inc. ($NVLS) and 10% Owner in Audentes Therapeutics, Inc. ($BOLD) and 10% Owner in SteadyMed Ltd. ($STDY) and 10% Owner in ShockWave Medical, Inc. ($SWAV) and 10% Owner in RHYTHM PHARMACEUTICALS, INC. ($RYTM) and 10% Owner in Editas Medicine, Inc. ($EDIT) and Director in AveXis, Inc. ($AVXS) and 10% Owner in ARVINAS INC. ($ARVN) and 10% Owner in Homology Medicines, Inc. ($FIXX) and Director in Homology Medicines, Inc. ($FIXX) and Director in Oncorus, Inc. ($ONCR) and 10% Owner in Revolution Medicines, Inc. ($RVMD) and 10% Owner in Black Diamond Therapeutics, Inc. ($BDTX) and 10% Owner in Frequency Therapeutics, Inc. ($FREQ) and Director in DFB Healthcare Acquisitions Corp. ($DFBH) and 10% Owner in Generation Bio Co. ($GBIO) and 10% Owner in Kiniksa Pharmaceuticals, Ltd. ($KNSA) and 10% Owner in Mirum Pharmaceuticals, Inc. ($MIRM) and 10% Owner in Cabaletta Bio, Inc. ($CABA) and 10% Owner in Werewolf Therapeutics, Inc. ($HOWL) and 10% Owner in Nkarta, Inc. ($NKTX) and 10% Owner in Edgewise Therapeutics, Inc. ($EWTX) and Director in DFP HEALTHCARE ACQUISITIONS CORP. ($DFPH) and Director in Deerfield Healthcare Technology Acquisitions Corp. ($DFHT) and 10% Owner in Terns Pharmaceuticals, Inc. ($TERN).
Latest Insider Trading Transactions of James E Flynn
Sentiment: All, ACRS, AFIB, DFBH, ADVM, ALIM, ALPN, ANNX, ATRS, ARNA, ARVN, LIFE, BOLD, ASPX, AVDL, AVXS, LECT, BDTX, CABA, CAMY.OB, CBIO, CNST, CYCC, CTMX, DFHTW, DFPHU, DRNA, DUSA, DVAX, EWTX, EDIT, EHTH, EMAG, FCSC, FREQ, GBIO, HITK, FIXX, ISPH, IVTY, ISTA, KNSA, LRMR, LOXO, NLNK, MNK, MDCO, MIRM, NEOS, NGSX, NURO, NTMD, NKTX, NXTM, ONCR, PRX, TARA, REPH, RGNX, RVMD, RYTM, RIGL, SDGR, SWAV, STDY, LANV, SYRS, EMLR, TERN, TWTI, TRIV, VNDA, CAQ, HOWL, XNPT, XERS
Page: < prev 1 ... 2 3 4 5 6 7 8 9 ... 10 next >
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
May 13 2015 | LIFE | aTYR PHARMA INC | Flynn James E | 10% Owner | Buy | P | 14.00 | 25,000 | 350,000 | 255,764 | 230.8 K to 255.8 K (+10.83 %) |
May 13 2015 | LIFE | aTYR PHARMA INC | Flynn James E | 10% Owner | Buy | C | 0.00 | 230,764 | 0 | 230,764 | 0 to 230.8 K |
May 13 2015 | LIFE | aTYR PHARMA INC | Flynn James E | 10% Owner | Buy | C | 0.00 | 230,764 | 0 | 230,764 | 0 to 230.8 K |
May 07 2015 | ASPX | Auspex Pharmaceuti ... | Flynn James E | 10% Owner | Sell | U | 0.00 | 973,379 | 0 | 0 | 973.4 K to 0 (-100.00 %) |
May 07 2015 | ASPX | Auspex Pharmaceuti ... | Flynn James E | 10% Owner | Sell | U | 0.00 | 849,426 | 0 | 0 | 849.4 K to 0 (-100.00 %) |
May 07 2015 | ASPX | Auspex Pharmaceuti ... | Flynn James E | 10% Owner | Sell | U | 0.00 | 1,182,943 | 0 | 0 | 1.2 M to 0 (-100.00 %) |
May 07 2015 | ASPX | Auspex Pharmaceuti ... | Flynn James E | 10% Owner | Sell | U | 0.00 | 953,286 | 0 | 0 | 953.3 K to 0 (-100.00 %) |
May 07 2015 | ASPX | Auspex Pharmaceuti ... | Flynn James E | 10% Owner | Sell | U | 0.00 | 490,069 | 0 | 0 | 490.1 K to 0 (-100.00 %) |
Apr 09 2015 | LECT | AxoGen, Inc. | Flynn James E | 10% Owner | Sell | S | 3.25 | 144,385 | 469,251 | 3,726,439 | 3.9 M to 3.7 M (-3.73 %) |
Mar 25 2015 | STDY | SteadyMed Ltd. | Flynn James E | 10% Owner | Option Exercise | C | 0.00 | 34,205 | 0 | 0 | |
Mar 25 2015 | STDY | SteadyMed Ltd. | Flynn James E | 10% Owner | Option Exercise | C | 0.00 | 34,205 | 0 | 0 | |
Mar 25 2015 | STDY | SteadyMed Ltd. | Flynn James E | 10% Owner | Buy | P | 8.50 | 558,440 | 4,746,740 | 823,529 | 265.1 K to 823.5 K (+210.66 %) |
Mar 25 2015 | STDY | SteadyMed Ltd. | Flynn James E | 10% Owner | Buy | P | 8.50 | 179,115 | 1,522,478 | 444,204 | 265.1 K to 444.2 K (+67.57 %) |
Mar 25 2015 | STDY | SteadyMed Ltd. | Flynn James E | 10% Owner | Buy | C | 0.00 | 265,089 | 0 | 265,089 | 0 to 265.1 K |
Mar 25 2015 | STDY | SteadyMed Ltd. | Flynn James E | 10% Owner | Buy | C | 0.00 | 265,089 | 0 | 265,089 | 0 to 265.1 K |
Mar 09 2015 | EHTH | eHealth, Inc. | Flynn James E | 10% Owner | Buy | P | 9.52 | 28,716 | 273,376 | 1,342,573 | 1.3 M to 1.3 M (+2.19 %) |
Mar 09 2015 | EHTH | eHealth, Inc. | Flynn James E | 10% Owner | Buy | P | 9.52 | 1,387 | 13,204 | 600,544 | 599.2 K to 600.5 K (+0.23 %) |
Jan 28 2015 | ASPX | Auspex Pharmaceuti ... | Flynn James E | 10% Owner | Buy | P | 56.50 | 192,240 | 10,861,560 | 973,379 | 781.1 K to 973.4 K (+24.61 %) |
Jan 28 2015 | ASPX | Auspex Pharmaceuti ... | Flynn James E | 10% Owner | Buy | P | 56.50 | 167,760 | 9,478,440 | 849,426 | 681.7 K to 849.4 K (+24.61 %) |
Jan 28 2015 | ASPX | Auspex Pharmaceuti ... | Flynn James E | 10% Owner | Buy | P | 56.50 | 566,825 | 32,025,613 | 1,182,943 | 616.1 K to 1.2 M (+92.00 %) |
Jan 28 2015 | ASPX | Auspex Pharmaceuti ... | Flynn James E | 10% Owner | Buy | P | 56.50 | 458,175 | 25,886,888 | 953,286 | 495.1 K to 953.3 K (+92.54 %) |
Jan 28 2015 | ASPX | Auspex Pharmaceuti ... | Flynn James E | 10% Owner | Buy | P | 56.50 | 115,000 | 6,497,500 | 490,069 | 375.1 K to 490.1 K (+30.66 %) |
Aug 11 2014 | EHTH | eHealth, Inc. | Flynn James E | 10% Owner | Buy | P | 21.05 | 1,731 | 36,438 | 1,251,903 | 1.3 M to 1.3 M (+0.14 %) |
Aug 11 2014 | EHTH | eHealth, Inc. | Flynn James E | 10% Owner | Buy | P | 21.05 | 1,400 | 29,470 | 1,012,685 | 1 M to 1 M (+0.14 %) |
Aug 05 2014 | EHTH | eHealth, Inc. | Flynn James E | 10% Owner | Buy | P | 20.99 | 2,085 | 43,764 | 1,250,172 | 1.2 M to 1.3 M (+0.17 %) |
Aug 05 2014 | EHTH | eHealth, Inc. | Flynn James E | 10% Owner | Buy | P | 20.99 | 1,685 | 35,368 | 1,011,285 | 1 M to 1 M (+0.17 %) |
Aug 05 2014 | EHTH | eHealth, Inc. | Flynn James E | 10% Owner | Buy | P | 20.75 | 78,853 | 1,636,200 | 1,248,087 | 1.2 M to 1.2 M (+6.74 %) |
Aug 05 2014 | EHTH | eHealth, Inc. | Flynn James E | 10% Owner | Buy | P | 20.40 | 7,122 | 145,289 | 1,169,234 | 1.2 M to 1.2 M (+0.61 %) |
Aug 05 2014 | EHTH | eHealth, Inc. | Flynn James E | 10% Owner | Buy | P | 20.75 | 63,738 | 1,322,564 | 1,009,600 | 945.9 K to 1 M (+6.74 %) |
Aug 05 2014 | EHTH | eHealth, Inc. | Flynn James E | 10% Owner | Buy | P | 20.40 | 5,757 | 117,443 | 945,862 | 940.1 K to 945.9 K (+0.61 %) |
Aug 05 2014 | EHTH | eHealth, Inc. | Flynn James E | 10% Owner | Buy | P | 19.40 | 13,272 | 257,477 | 1,162,112 | 1.1 M to 1.2 M (+1.16 %) |
Aug 05 2014 | EHTH | eHealth, Inc. | Flynn James E | 10% Owner | Buy | P | 19.04 | 80,904 | 1,540,412 | 1,148,840 | 1.1 M to 1.1 M (+7.58 %) |
Aug 05 2014 | EHTH | eHealth, Inc. | Flynn James E | 10% Owner | Buy | P | 19.40 | 10,728 | 208,123 | 940,105 | 929.4 K to 940.1 K (+1.15 %) |
Aug 05 2014 | EHTH | eHealth, Inc. | Flynn James E | 10% Owner | Buy | P | 19.04 | 65,396 | 1,245,140 | 929,377 | 864 K to 929.4 K (+7.57 %) |
Aug 06 2014 | LOXO | Loxo Oncology, Inc ... | Flynn James E | 10% Owner | Option Exercise | C | 0.00 | 222,839 | 0 | 0 | |
Aug 06 2014 | LOXO | Loxo Oncology, Inc ... | Flynn James E | 10% Owner | Option Exercise | C | 0.00 | 279,051 | 0 | 0 | |
Aug 06 2014 | LOXO | Loxo Oncology, Inc ... | Flynn James E | 10% Owner | Buy | P | 13.05 | 77,256 | 1,008,191 | 296,125 | 218.9 K to 296.1 K (+35.30 %) |
Aug 06 2014 | LOXO | Loxo Oncology, Inc ... | Flynn James E | 10% Owner | Buy | P | 13.00 | 218,869 | 2,845,297 | 218,869 | 0 to 218.9 K |
Aug 06 2014 | LOXO | Loxo Oncology, Inc ... | Flynn James E | 10% Owner | Buy | P | 13.05 | 62,400 | 814,320 | 239,300 | 176.9 K to 239.3 K (+35.27 %) |
Aug 06 2014 | LOXO | Loxo Oncology, Inc ... | Flynn James E | 10% Owner | Buy | P | 13.00 | 176,900 | 2,299,700 | 176,900 | 0 to 176.9 K |
Aug 06 2014 | LOXO | Loxo Oncology, Inc ... | Flynn James E | 10% Owner | Buy | P | 13.00 | 246,631 | 3,206,203 | 469,470 | 222.8 K to 469.5 K (+110.68 %) |
Aug 06 2014 | LOXO | Loxo Oncology, Inc ... | Flynn James E | 10% Owner | Buy | P | 13.00 | 307,600 | 3,998,800 | 586,651 | 279.1 K to 586.7 K (+110.23 %) |
Aug 06 2014 | LOXO | Loxo Oncology, Inc ... | Flynn James E | 10% Owner | Buy | C | 0.00 | 222,839 | 0 | 222,839 | 0 to 222.8 K |
Aug 06 2014 | LOXO | Loxo Oncology, Inc ... | Flynn James E | 10% Owner | Buy | C | 0.00 | 279,051 | 0 | 279,051 | 0 to 279.1 K |
Aug 05 2014 | AAVL | Adverum Biotechnol ... | Flynn James E | 10% Owner | Option Exercise | C | 0.00 | 531,208 | 0 | 0 | |
Aug 05 2014 | AAVL | Adverum Biotechnol ... | Flynn James E | 10% Owner | Option Exercise | C | 0.00 | 147,410 | 0 | 0 | |
Aug 05 2014 | AAVL | Adverum Biotechnol ... | Flynn James E | 10% Owner | Option Exercise | C | 0.00 | 184,594 | 0 | 0 | |
Aug 05 2014 | AAVL | Adverum Biotechnol ... | Flynn James E | 10% Owner | Buy | P | 24.57 | 31,650 | 777,641 | 627,267 | 595.6 K to 627.3 K (+5.31 %) |
Aug 05 2014 | AAVL | Adverum Biotechnol ... | Flynn James E | 10% Owner | Buy | P | 26.35 | 49,981 | 1,316,999 | 595,617 | 545.6 K to 595.6 K (+9.16 %) |
Aug 05 2014 | AAVL | Adverum Biotechnol ... | Flynn James E | 10% Owner | Buy | P | 26.14 | 27,600 | 721,464 | 545,636 | 518 K to 545.6 K (+5.33 %) |
Aug 05 2014 | AAVL | Adverum Biotechnol ... | Flynn James E | 10% Owner | Buy | P | 27.54 | 12,400 | 341,496 | 518,036 | 505.6 K to 518 K (+2.45 %) |
Aug 05 2014 | AAVL | Adverum Biotechnol ... | Flynn James E | 10% Owner | Buy | P | 26.42 | 219,864 | 5,808,807 | 505,636 | 285.8 K to 505.6 K (+76.94 %) |
Aug 05 2014 | AAVL | Adverum Biotechnol ... | Flynn James E | 10% Owner | Buy | P | 25.79 | 18,700 | 482,273 | 285,772 | 267.1 K to 285.8 K (+7.00 %) |
Aug 05 2014 | AAVL | Adverum Biotechnol ... | Flynn James E | 10% Owner | Buy | P | 25.52 | 9,800 | 250,096 | 267,072 | 257.3 K to 267.1 K (+3.81 %) |
Aug 05 2014 | AAVL | Adverum Biotechnol ... | Flynn James E | 10% Owner | Buy | P | 25.41 | 201,972 | 5,132,109 | 257,272 | 55.3 K to 257.3 K (+365.23 %) |
Aug 05 2014 | AAVL | Adverum Biotechnol ... | Flynn James E | 10% Owner | Buy | P | 17.00 | 55,300 | 940,100 | 55,300 | 0 to 55.3 K |
Aug 05 2014 | AAVL | Adverum Biotechnol ... | Flynn James E | 10% Owner | Buy | P | 24.57 | 25,600 | 628,992 | 507,200 | 481.6 K to 507.2 K (+5.32 %) |
Aug 05 2014 | AAVL | Adverum Biotechnol ... | Flynn James E | 10% Owner | Buy | P | 26.35 | 40,400 | 1,064,540 | 481,600 | 441.2 K to 481.6 K (+9.16 %) |
Aug 05 2014 | AAVL | Adverum Biotechnol ... | Flynn James E | 10% Owner | Buy | P | 26.14 | 22,400 | 585,536 | 441,200 | 418.8 K to 441.2 K (+5.35 %) |
Aug 05 2014 | AAVL | Adverum Biotechnol ... | Flynn James E | 10% Owner | Buy | P | 27.54 | 10,100 | 278,154 | 418,800 | 408.7 K to 418.8 K (+2.47 %) |
Aug 05 2014 | AAVL | Adverum Biotechnol ... | Flynn James E | 10% Owner | Buy | P | 26.42 | 177,700 | 4,694,834 | 408,700 | 231 K to 408.7 K (+76.93 %) |
Aug 05 2014 | AAVL | Adverum Biotechnol ... | Flynn James E | 10% Owner | Buy | P | 25.79 | 15,100 | 389,429 | 231,000 | 215.9 K to 231 K (+6.99 %) |
Aug 05 2014 | AAVL | Adverum Biotechnol ... | Flynn James E | 10% Owner | Buy | P | 25.52 | 7,900 | 201,608 | 215,900 | 208 K to 215.9 K (+3.80 %) |
Aug 05 2014 | AAVL | Adverum Biotechnol ... | Flynn James E | 10% Owner | Buy | P | 25.41 | 163,300 | 4,149,453 | 208,000 | 44.7 K to 208 K (+365.32 %) |
Aug 05 2014 | AAVL | Adverum Biotechnol ... | Flynn James E | 10% Owner | Buy | P | 17.00 | 44,700 | 759,900 | 44,700 | 0 to 44.7 K |
Aug 05 2014 | AAVL | Adverum Biotechnol ... | Flynn James E | 10% Owner | Buy | P | 17.00 | 123,077 | 2,092,309 | 654,285 | 531.2 K to 654.3 K (+23.17 %) |
Aug 05 2014 | AAVL | Adverum Biotechnol ... | Flynn James E | 10% Owner | Buy | P | 17.00 | 34,223 | 581,791 | 181,633 | 147.4 K to 181.6 K (+23.22 %) |
Aug 05 2014 | AAVL | Adverum Biotechnol ... | Flynn James E | 10% Owner | Buy | P | 17.00 | 42,700 | 725,900 | 227,294 | 184.6 K to 227.3 K (+23.13 %) |
Aug 05 2014 | AAVL | Adverum Biotechnol ... | Flynn James E | 10% Owner | Buy | C | 0.00 | 531,208 | 0 | 531,208 | 0 to 531.2 K |
Aug 05 2014 | AAVL | Adverum Biotechnol ... | Flynn James E | 10% Owner | Buy | C | 0.00 | 147,410 | 0 | 147,410 | 0 to 147.4 K |
Aug 05 2014 | AAVL | Adverum Biotechnol ... | Flynn James E | 10% Owner | Buy | C | 0.00 | 184,594 | 0 | 184,594 | 0 to 184.6 K |
Apr 22 2014 | TRIV | TriVascular Techno ... | Flynn James E | 10% Owner | Option Exercise | C | 0.00 | 253,384 | 0 | 0 | |
Apr 22 2014 | TRIV | TriVascular Techno ... | Flynn James E | 10% Owner | Option Exercise | C | 0.00 | 221,118 | 0 | 0 | |
Apr 22 2014 | TRIV | TriVascular Techno ... | Flynn James E | 10% Owner | Option Exercise | C | 0.00 | 71,333 | 0 | 0 | |
Apr 22 2014 | TRIV | TriVascular Techno ... | Flynn James E | 10% Owner | Option Exercise | C | 0.00 | 86,834 | 0 | 0 | |
Apr 22 2014 | TRIV | TriVascular Techno ... | Flynn James E | 10% Owner | Buy | P | 11.97 | 75,480 | 903,126 | 261,143 | 185.7 K to 261.1 K (+40.65 %) |
Apr 22 2014 | TRIV | TriVascular Techno ... | Flynn James E | 10% Owner | Buy | P | 11.97 | 94,520 | 1,130,941 | 324,524 | 230 K to 324.5 K (+41.09 %) |
Apr 22 2014 | TRIV | TriVascular Techno ... | Flynn James E | 10% Owner | Buy | P | 12.29 | 19,980 | 245,468 | 185,663 | 165.7 K to 185.7 K (+12.06 %) |
Apr 22 2014 | TRIV | TriVascular Techno ... | Flynn James E | 10% Owner | Buy | P | 12.29 | 25,020 | 307,388 | 230,004 | 205 K to 230 K (+12.21 %) |
Apr 22 2014 | TRIV | TriVascular Techno ... | Flynn James E | 10% Owner | Buy | P | 12.00 | 340,425 | 4,085,100 | 593,809 | 253.4 K to 593.8 K (+134.35 %) |
Apr 22 2014 | TRIV | TriVascular Techno ... | Flynn James E | 10% Owner | Buy | P | 12.00 | 297,075 | 3,564,900 | 518,193 | 221.1 K to 518.2 K (+134.35 %) |
Apr 22 2014 | TRIV | TriVascular Techno ... | Flynn James E | 10% Owner | Buy | P | 12.00 | 94,350 | 1,132,200 | 165,683 | 71.3 K to 165.7 K (+132.27 %) |
Apr 22 2014 | TRIV | TriVascular Techno ... | Flynn James E | 10% Owner | Buy | P | 12.00 | 118,150 | 1,417,800 | 204,984 | 86.8 K to 205 K (+136.06 %) |
Apr 22 2014 | TRIV | TriVascular Techno ... | Flynn James E | 10% Owner | Buy | C | 0.00 | 253,384 | 0 | 253,384 | 0 to 253.4 K |
Apr 22 2014 | TRIV | TriVascular Techno ... | Flynn James E | 10% Owner | Buy | C | 0.00 | 221,118 | 0 | 221,118 | 0 to 221.1 K |
Apr 22 2014 | TRIV | TriVascular Techno ... | Flynn James E | 10% Owner | Buy | C | 0.00 | 71,333 | 0 | 71,333 | 0 to 71.3 K |
Apr 22 2014 | TRIV | TriVascular Techno ... | Flynn James E | 10% Owner | Buy | C | 0.00 | 86,834 | 0 | 86,834 | 0 to 86.8 K |
Feb 04 2014 | DRNA | Dicerna Pharmaceut ... | Flynn James E | 10% Owner | Option Exercise | C | 0.00 | 572,142 | 0 | 0 | |
Feb 04 2014 | DRNA | Dicerna Pharmaceut ... | Flynn James E | 10% Owner | Option Exercise | C | 0.00 | 499,285 | 0 | 0 | |
Feb 04 2014 | DRNA | Dicerna Pharmaceut ... | Flynn James E | 10% Owner | Option Exercise | C | 0.00 | 161,071 | 0 | 0 | |
Feb 04 2014 | DRNA | Dicerna Pharmaceut ... | Flynn James E | 10% Owner | Option Exercise | C | 0.00 | 196,071 | 0 | 0 | |
Feb 04 2014 | DRNA | Dicerna Pharmaceut ... | Flynn James E | 10% Owner | Buy | P | 15.00 | 400,500 | 6,007,500 | 972,642 | 572.1 K to 972.6 K (+70.00 %) |
Feb 04 2014 | DRNA | Dicerna Pharmaceut ... | Flynn James E | 10% Owner | Buy | P | 15.00 | 349,500 | 5,242,500 | 848,785 | 499.3 K to 848.8 K (+70.00 %) |
Feb 04 2014 | DRNA | Dicerna Pharmaceut ... | Flynn James E | 10% Owner | Buy | P | 15.00 | 112,000 | 1,680,000 | 273,071 | 161.1 K to 273.1 K (+69.53 %) |
Feb 04 2014 | DRNA | Dicerna Pharmaceut ... | Flynn James E | 10% Owner | Buy | P | 15.00 | 138,000 | 2,070,000 | 334,071 | 196.1 K to 334.1 K (+70.38 %) |
Feb 04 2014 | DRNA | Dicerna Pharmaceut ... | Flynn James E | 10% Owner | Buy | C | 0.00 | 572,142 | 0 | 972,642 | 400.5 K to 972.6 K (+142.86 %) |
Feb 04 2014 | DRNA | Dicerna Pharmaceut ... | Flynn James E | 10% Owner | Buy | C | 0.00 | 499,285 | 0 | 848,785 | 349.5 K to 848.8 K (+142.86 %) |
Feb 04 2014 | DRNA | Dicerna Pharmaceut ... | Flynn James E | 10% Owner | Buy | C | 0.00 | 161,071 | 0 | 273,071 | 112 K to 273.1 K (+143.81 %) |
Feb 04 2014 | DRNA | Dicerna Pharmaceut ... | Flynn James E | 10% Owner | Buy | C | 0.00 | 196,071 | 0 | 334,071 | 138 K to 334.1 K (+142.08 %) |
Feb 11 2014 | ASPX | Auspex Pharmaceuti ... | Flynn James E | 10% Owner | Option Exercise | C | 0.00 | 2,323,086 | 0 | 0 | |
Feb 11 2014 | ASPX | Auspex Pharmaceuti ... | Flynn James E | 10% Owner | Option Exercise | C | 0.00 | 2,027,262 | 0 | 0 | |
Feb 11 2014 | ASPX | Auspex Pharmaceuti ... | Flynn James E | 10% Owner | Option Exercise | C | 0.00 | 654,002 | 0 | 0 | |
Feb 11 2014 | ASPX | Auspex Pharmaceuti ... | Flynn James E | 10% Owner | Option Exercise | C | 0.00 | 796,114 | 0 | 0 | |
Feb 11 2014 | ASPX | Auspex Pharmaceuti ... | Flynn James E | 10% Owner | Buy | P | 12.00 | 280,350 | 3,364,200 | 796,591 | 516.2 K to 796.6 K (+54.31 %) |
Feb 11 2014 | ASPX | Auspex Pharmaceuti ... | Flynn James E | 10% Owner | Buy | P | 12.00 | 244,650 | 2,935,800 | 695,152 | 450.5 K to 695.2 K (+54.31 %) |
Feb 11 2014 | ASPX | Auspex Pharmaceuti ... | Flynn James E | 10% Owner | Buy | P | 12.00 | 78,400 | 940,800 | 223,733 | 145.3 K to 223.7 K (+53.95 %) |
Feb 11 2014 | ASPX | Auspex Pharmaceuti ... | Flynn James E | 10% Owner | Buy | P | 12.00 | 96,600 | 1,159,200 | 273,514 | 176.9 K to 273.5 K (+54.60 %) |
Feb 11 2014 | ASPX | Auspex Pharmaceuti ... | Flynn James E | 10% Owner | Buy | C | 0.00 | 516,241 | 0 | 796,591 | 280.4 K to 796.6 K (+184.14 %) |
Feb 11 2014 | ASPX | Auspex Pharmaceuti ... | Flynn James E | 10% Owner | Buy | C | 0.00 | 450,502 | 0 | 695,152 | 244.7 K to 695.2 K (+184.14 %) |
Feb 11 2014 | ASPX | Auspex Pharmaceuti ... | Flynn James E | 10% Owner | Buy | C | 0.00 | 145,333 | 0 | 223,733 | 78.4 K to 223.7 K (+185.37 %) |
Feb 11 2014 | ASPX | Auspex Pharmaceuti ... | Flynn James E | 10% Owner | Buy | C | 0.00 | 176,914 | 0 | 273,514 | 96.6 K to 273.5 K (+183.14 %) |
Jul 18 2013 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | S | 1.20 | 187,149 | 224,579 | 0 | |
Jul 18 2013 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | S | 1.20 | 116,172 | 139,406 | 0 | |
Jul 18 2013 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | S | 1.20 | 39,249 | 47,099 | 0 | |
Jul 18 2013 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | S | 1.20 | 21,414 | 25,697 | 0 | |
Jul 18 2013 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | C | 0.35 | 9,258 | 3,240 | 0 | |
Jul 18 2013 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | C | 0.35 | 5,748 | 2,012 | 0 | |
Jul 18 2013 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | C | 0.35 | 1,938 | 678 | 0 | |
Jul 18 2013 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | C | 0.35 | 1,056 | 370 | 0 | |
Jul 18 2013 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | C | 0.30 | 19,620 | 5,886 | 0 | |
Jul 18 2013 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | C | 0.30 | 12,179 | 3,654 | 0 | |
Jul 18 2013 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | C | 0.30 | 4,114 | 1,234 | 0 | |
Jul 18 2013 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | C | 0.30 | 2,243 | 673 | 0 | |
Jul 18 2013 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | C | 0.74 | 21,213 | 15,613 | 0 | |
Jul 18 2013 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | C | 0.74 | 13,168 | 9,692 | 0 | |
Jul 18 2013 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | C | 0.74 | 4,448 | 3,274 | 0 | |
Jul 18 2013 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | C | 0.74 | 2,426 | 1,786 | 0 | |
Jul 18 2013 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 0.06 | 14,005,557 | 785,712 | 0 | 14 M to 0 (-100.00 %) |
Jul 18 2013 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Buy | C | 0.35 | 2,830,978 | 990,842 | 14,005,557 | 11.2 M to 14 M (+25.33 %) |
Jul 18 2013 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Buy | C | 0.30 | 7,323,275 | 2,196,983 | 11,174,579 | 3.9 M to 11.2 M (+190.15 %) |
Jul 18 2013 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Buy | C | 0.74 | 3,714,455 | 2,733,839 | 3,851,304 | 136.8 K to 3.9 M (+2,714.27 %) |
Jul 18 2013 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 0.06 | 8,694,231 | 487,746 | 0 | 8.7 M to 0 (-100.00 %) |
Jul 18 2013 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Buy | C | 0.35 | 1,757,664 | 615,182 | 8,694,231 | 6.9 M to 8.7 M (+25.34 %) |
Jul 18 2013 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Buy | C | 0.30 | 4,545,880 | 1,363,764 | 6,936,567 | 2.4 M to 6.9 M (+190.15 %) |
Jul 18 2013 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Buy | C | 0.74 | 2,305,753 | 1,697,034 | 2,390,687 | 84.9 K to 2.4 M (+2,714.76 %) |
Jul 18 2013 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 0.06 | 2,974,566 | 166,873 | 0 | 3 M to 0 (-100.00 %) |
Jul 18 2013 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Buy | C | 0.35 | 592,613 | 207,415 | 2,974,566 | 2.4 M to 3 M (+24.88 %) |
Jul 18 2013 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Buy | C | 0.30 | 1,535,573 | 460,672 | 2,381,953 | 846.4 K to 2.4 M (+181.43 %) |
Jul 18 2013 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Buy | C | 0.74 | 778,856 | 573,238 | 846,380 | 67.5 K to 846.4 K (+1,153.45 %) |
Jul 18 2013 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Sell | S | 0.06 | 1,619,176 | 90,836 | 0 | 1.6 M to 0 (-100.00 %) |
Jul 18 2013 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Buy | C | 0.35 | 322,911 | 113,019 | 1,619,176 | 1.3 M to 1.6 M (+24.91 %) |
Jul 18 2013 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Buy | C | 0.30 | 837,215 | 251,165 | 1,296,265 | 459.1 K to 1.3 M (+182.38 %) |
Jul 18 2013 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Buy | C | 0.74 | 424,798 | 312,651 | 459,050 | 34.3 K to 459.1 K (+1,240.21 %) |
Jan 15 2013 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | A | 0.35 | 3,086 | 1,080 | 9,258 | |
Jan 15 2013 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | A | 0.35 | 1,916 | 671 | 5,748 | |
Jan 15 2013 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | A | 0.35 | 646 | 226 | 1,938 | |
Jan 15 2013 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | A | 0.35 | 352 | 123 | 1,056 | |
Nov 16 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | A | 0.35 | 1,543 | 540 | 6,172 | |
Nov 16 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | A | 0.35 | 958 | 335 | 3,832 | |
Nov 16 2012 | EMLR | Talon Therapeutics ... | Flynn James E | Director | Option Exercise | A | 0.35 | 323 | 113 | 1,292 |